A new methodology termed selective organ targeting (SORT) was recently developed that
enables controllable delivery of nucleic acids to target tissues. SORT lipid nanoparticles …

Lipid nanoparticles (LNPs) are a clinically mature technology for the delivery of genetic
medicines but have limited therapeutic applications due to liver accumulation. Recently, our …

The earliest example of in vivo expression of exogenous mRNA is by direct intramuscular
injection in mice without the aid of a delivery vehicle. The current state of the art for …

Lipid nanoparticle (LNP)-based drug delivery systems have become the most clinically
advanced non-viral delivery technology. LNPs can encapsulate and deliver a wide variety of …

The last few years have witnessed a great advance in the development of nonviral systems
for in vivo targeted delivery of nucleic acids. Lipid nanoparticles (LNPs) are the most …

Conspectus Since the US Food and Drug Administration (FDA) granted emergency use
authorization for two mRNA vaccines against SARS-CoV-2, mRNA-based technology has …

Messenger RNA (mRNA) can treat genetic disease using protein replacement or genome
editing approaches but requires a suitable carrier to circumnavigate biological barriers and …

The success of mRNA vaccines during the COVID-19 pandemic has greatly accelerated the
development of mRNA therapy. mRNA is a negatively charged nucleic acid that serves as a …

Thousands of human diseases could be treated by selectively controlling the expression of
specific proteins in vivo. We demonstrate a new series of alkenyl amino alcohol (AAA) …

Lipid nanoparticles (LNPs) have emerged as a viable, clinically-validated platform for the
delivery of mRNA therapeutics. LNPs have been utilized as mRNA delivery systems for …